Int J Clin Oncol. 2024 Apr 30. doi: 10.1007/s10147-024-02531-1. Online ahead of print.
NO ABSTRACT
PMID:38687406 | DOI:10.1007/s10147-024-02531-1
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan
by | May 1, 2024 | Publications | 0 comments